| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |